Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/12458337http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/12458337http://www.w3.org/2000/01/rdf-schema#comment"

Purpose

In recent years, the use of immunotherapy for malignant tumors has been proposed. To explore the significance of immunotherapy for lung cancer, we examined two systems : the HLA class I and cancer-reactive CTL system, and the Fas-FasL system.

Methods

HLA class I (HLA-A, -B, and -C) antigens were determined in 61 patients with lung cancer and in 30 healthy controls. The HLA class I phenotype was investigated by serological techniques. HLA-A2 alleles were investigated by polymerase chain reaction sequence-specific primer analysis. We analyzed lymphocytes isolated from 61 patients with two-color surface labeling and flow cytometry. Furthermore, we analyzed sFas and sFasL expression by enzyme-linked immunosorbent assay (ELISA). We also examined lung cancer cell line-induced apoptosis of CD8(+) lymphocytes using confocal laser scanning microscopy.

Results

The HLA-A2 allele was observed in 27 of 61 patients with lung cancer. There were no differences in HLA-A2 allele classifications between lung cancer patients and controls. Thirty-six of the 61 lung cancer patients (57%) had elevated levels of sFas, and 16 of the 61 patients (26.2%) had elevated levels of sFasL. The sFas level of lung cancers with HLA-A2 was significantly higher than that of cancers without HLA-A2 ( P<0.01). This tendency was observed in every lung cancer tissue type, and the sFas levels of lung cancers with HLA-A2 associated significantly with the CTL levels of lung cancers with HLA-A2. Furthermore, compared to lung cancers without HLA-A2, CD8(+) T-cell levels were elevated in lung cancers with HLA-A2. In contrast, sFas levels of non-small cell lung cancers without HLA-A2 were higher than those in lung cancers with HLA-A2. In an in vitro experiment using lung cancer cell lines, we observed apoptosis of CD8(+) lymphocytes induced by lung cancer cells. Lung cancer-reactive CTLs are mobilized easily by restriction of HLA-A2, but this restriction is not always specific. In addition, FasL derived from lung cancer cells can induce apoptosis of CD8(+) T-cells, and the frequency of this phenomenon is increased in small cell lung cancers without HLA-A2.

Conclusion

Our findings suggest that the effect of immunotherapy may be insufficient for non-small cell lung cancer without HLA-A2."xsd:string
http://purl.uniprot.org/citations/12458337http://purl.org/dc/terms/identifier"doi:10.1007/s00432-002-0381-y"xsd:string
http://purl.uniprot.org/citations/12458337http://purl.uniprot.org/core/author"Muramatsu M."xsd:string
http://purl.uniprot.org/citations/12458337http://purl.uniprot.org/core/author"Nomura S."xsd:string
http://purl.uniprot.org/citations/12458337http://purl.uniprot.org/core/author"Yamaguchi K."xsd:string
http://purl.uniprot.org/citations/12458337http://purl.uniprot.org/core/author"Kanazawa S."xsd:string
http://purl.uniprot.org/citations/12458337http://purl.uniprot.org/core/author"Fukuhara S."xsd:string
http://purl.uniprot.org/citations/12458337http://purl.uniprot.org/core/author"Kuwana M."xsd:string
http://purl.uniprot.org/citations/12458337http://purl.uniprot.org/core/author"Yoshimura C."xsd:string
http://purl.uniprot.org/citations/12458337http://purl.uniprot.org/core/date"2002"xsd:gYear
http://purl.uniprot.org/citations/12458337http://purl.uniprot.org/core/name"J Cancer Res Clin Oncol"xsd:string
http://purl.uniprot.org/citations/12458337http://purl.uniprot.org/core/pages"581-588"xsd:string
http://purl.uniprot.org/citations/12458337http://purl.uniprot.org/core/title"Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2."xsd:string
http://purl.uniprot.org/citations/12458337http://purl.uniprot.org/core/volume"128"xsd:string
http://purl.uniprot.org/citations/12458337http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/12458337
http://purl.uniprot.org/citations/12458337http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/12458337
http://purl.uniprot.org/uniprot/#_A0A0A7C548-mappedCitation-12458337http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/12458337
http://purl.uniprot.org/uniprot/#_A0A0A7C551-mappedCitation-12458337http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/12458337
http://purl.uniprot.org/uniprot/#_A0A0G2R0N3-mappedCitation-12458337http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/12458337
http://purl.uniprot.org/uniprot/#_A0A0G2R0N4-mappedCitation-12458337http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/12458337
http://purl.uniprot.org/uniprot/#_A0A0G2R0N5-mappedCitation-12458337http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/12458337
http://purl.uniprot.org/uniprot/#_A0A076JXB7-mappedCitation-12458337http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/12458337
http://purl.uniprot.org/uniprot/#_A0A076L0P9-mappedCitation-12458337http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/12458337
http://purl.uniprot.org/uniprot/#_A0A0A0YLW6-mappedCitation-12458337http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/12458337
▶